No relevant midbrain atrophy in Parkinson's disease

Area of Science:

• Neuroimaging
• Neurology
• Radiology

Background:

• Parkinson's disease (PD) is characterized by the degeneration of dopaminergic neurons.
• Midbrain structural changes may occur in PD, but their relationship with dopaminergic deficits is unclear.

Purpose of the Study:

• To determine if midbrain atrophy is present in Parkinson's disease (PD).
• To assess if midbrain atrophy can serve as a marker for striatal dopaminergic degeneration in PD.

Main Methods:

• 150 PD patients and 155 controls underwent dopamine transporter (DAT) SPECT ([¹²³I]FP-CIT) and 1.5T MRI.
• Midbrain atrophy was quantified using midbrain-to-pons ratios from MRI.
• DAT binding was analyzed using region-of-interest and voxel-based methods.

Main Results:

• PD patients exhibited slightly lower midbrain-to-pons ratios compared to controls (P < 0.05).
• No significant correlation was found between midbrain atrophy and striatal or extrastriatal DAT binding in PD patients or controls.

Conclusions:

• Mild midbrain atrophy is detectable in Parkinson's disease (PD) via MRI.
• Midbrain atrophy in PD is not associated with the degree of striatal dopaminergic dysfunction.
• Midbrain atrophy measurements are not clinically useful predictors of dopamine function in PD.